Last reviewed 2026-04-20 · How we verify

Famtozinameran 5 to 11 Years of age (famtozinameran-5-to-11-years-of-age)

Pfizer · FDA-approved active Vaccine Quality 22/100

Famtozinameran 5 to 11 Years of age (generic name: famtozinameran-5-to-11-years-of-age) is a Monoclonal antibody Vaccine drug developed by Pfizer. It is currently FDA-approved for Prevention of COVID-19 in individuals 5 years of age and older.

Famtozinameran is a COVID-19 prevention medication developed by Pfizer Inc. It works by targeting the SARS-CoV-2 virus. The key indication is for individuals 5 years of age and older. Famtozinameran is a marketed drug with significant commercial success, generating $21.2B in revenue. It has a novel mechanism of action, making it a valuable addition to the COVID-19 prevention landscape. The drug's clinical differentiation lies in its ability to prevent COVID-19 in a younger age group. Its commercial significance is evident in its high revenue generation.

At a glance

Generic name	famtozinameran-5-to-11-years-of-age
Sponsor	Pfizer
Drug class	Monoclonal antibody
Target	SARS-CoV-2 spike protein
Modality	Vaccine
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

Prevention of COVID-19 in individuals 5 years of age and older

Common side effects

No common side effects on file.

Drug interactions

Live vaccines
Interferons
Immunosuppressive therapies
Antiviral medications
Corticosteroids
Other vaccines
Blood thinners
Medications that affect blood clotting

Key clinical trials

Korea Comirnaty Post-marketing Surveillance

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Famtozinameran 5 to 11 Years of age CI brief — competitive landscape report
Famtozinameran 5 to 11 Years of age updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Famtozinameran 5 to 11 Years of age

What is Famtozinameran 5 to 11 Years of age?

Famtozinameran 5 to 11 Years of age (famtozinameran-5-to-11-years-of-age) is a Monoclonal antibody drug developed by Pfizer, indicated for Prevention of COVID-19 in individuals 5 years of age and older.

What is Famtozinameran 5 to 11 Years of age used for?

Famtozinameran 5 to 11 Years of age is indicated for Prevention of COVID-19 in individuals 5 years of age and older.

Who makes Famtozinameran 5 to 11 Years of age?

Famtozinameran 5 to 11 Years of age is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of Famtozinameran 5 to 11 Years of age?

famtozinameran-5-to-11-years-of-age is the generic (nonproprietary) name of Famtozinameran 5 to 11 Years of age.

What drug class is Famtozinameran 5 to 11 Years of age in?

Famtozinameran 5 to 11 Years of age belongs to the Monoclonal antibody class. See all Monoclonal antibody drugs at /class/monoclonal-antibody.

What development phase is Famtozinameran 5 to 11 Years of age in?

Famtozinameran 5 to 11 Years of age is FDA-approved (marketed).

What does Famtozinameran 5 to 11 Years of age target?

Famtozinameran 5 to 11 Years of age targets SARS-CoV-2 spike protein and is a Monoclonal antibody.

Drug class: All Monoclonal antibody drugs
Target: All drugs targeting SARS-CoV-2 spike protein
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Prevention of COVID-19 in individuals 5 years of age and older
Compare: Famtozinameran 5 to 11 Years of age vs similar drugs
Pricing: Famtozinameran 5 to 11 Years of age cost, discount & access